AI news

Tushen Zhihe raises hundreds of millions of yuan for protein design and preclinical R&D

By 机器之心0 viewsSource: 机器之心
AI protein design and computational–wet-lab development at Tushen Zhihe

Tushen Zhihe reports Pre-A and Pre-A+ funding for internal pipelines, ToursynClaw and team expansion. The company describes computational/wet-lab loops and candidate development; these milestones do not establish clinical efficacy.

Recently, Wuxi Tushen Zhihe Artificial Intelligence Technology Co., Ltd. (“Tushen Zhihe”) completed successive Pre-A and Pre-A+ rounds totaling hundreds of millions of yuan. The Pre-A was led by Shanghai Science and Technology Innovation Group, with Zhongsheng Yinling, Zhoushan Tuyi and others participating. Jinding Capital, MegaRobo, Zero2IPO Holdings and others jointly invested in the Pre-A+. Kaicheng Capital serves as its long-term exclusive financial adviser.

Article illustration

At this industry turning point, as AI for Science accelerates from proof of concept toward commercial deployment, Tushen Zhihe has secured substantial investment from prominent funds and major industry players, further underscoring capital-market recognition of the company’s AI protein-design technology and commercialization prospects.

The funding will primarily support three areas:

  • First, advancing its internal pipeline, particularly supporting multiple programs toward IND submissions and progressing innovative candidates from early discovery to preclinical candidate (PCC) selection and IND-enabling studies;
  • Second, upgrading the ToursynClaw integrated AI drug-design platform, strengthening proprietary protein-generation and optimization models and improving the design–experiment–feedback–redesign computational and wet-lab loop to improve success in multimodal drug design;
  • Third, strengthening operations and market expansion, expanding AI algorithms, biomedical R&D, business development and commercialization teams, deepening strategic partnerships with leading Chinese and multinational pharmaceutical companies, and accelerating out-licensing and joint development.

Founded in 2023, Tushen Zhihe focuses on AI protein design. It describes itself as an AI biopharmaceutical factory with AI super-agents at its core, a computational/wet-lab closed loop as its production line and a multimodal product library as its output. Its interdisciplinary AI and life-sciences team includes people from Shanghai Jiao Tong University, Johns Hopkins University, the University of Cambridge, University College London and other prominent institutions, with extensive AI research and commercialization experience.

Technically, the company has developed proprietary protein-design models and extensively optimized specialist open-source state-of-the-art models, forming its own technology system across the protein-design workflow. Its ToursynClaw scientific-agent platform focuses on biomedicine and a multimodal product library, addressing difficult-to-drug targets such as GPCRs and intrinsically disordered protein regions, alongside complex molecules including antibodies and cyclic peptides. For targets resistant to traditional approaches, the company says AI generation, structure prediction and affinity optimization can rapidly produce highly active, stable protein candidates, substantially expanding druggable possibilities.

ToursynClaw connects the complete design–experiment–feedback–redesign loop. Automated wet-lab execution agents integrate laboratory equipment for high-throughput validation, with data returned in real time to dedicated evaluation and risk-prediction models to refine design strategies. The company reports experimental validation in more than a hundred antibody-engineering projects, a fourteen-day computational/wet-lab validation cycle and more than 5,000 experimental data records. This closely connects AI design with laboratory validation and substantially shortens development from target discovery to candidate confirmation.

Article illustration

The new financing has attracted well-known state-backed platforms, specialist industrial investors, market-oriented institutions and other sources of capital to invest together, combining strategic depth with the value of industrial collaboration.

Founder and CEO Dr. Wang Yuguang said: “We thank our investors for their trust and support and Kaicheng Capital for its professional assistance. Since AlphaFold 2’s important breakthrough in protein-structure prediction, AI applications in protein engineering and biopharmaceuticals have deepened. We have always believed that AI drug discovery should be measured not just by benchmarks but by whether it designs molecules with actual functional activity, promising drug-development potential and value for further development.” He continued: “Moving from discovery to creation was our original reason for choosing AI protein design. We will keep iterating ToursynClaw, deepen coordination between AI design and automated experiments, and improve design strategies through real experimental feedback. We will also accelerate internal programs and industry partnerships to turn platform capabilities into practical R&D outcomes. We hope to gradually build a biologics-development system centered on AI super-agents and computational/wet-lab loops, allowing AI not only to assist molecular discovery but to participate continuously in drug creation.”

Shanghai Science and Technology Innovation Group said: “AI4S in biomedicine has been one of our most closely watched investment directions in recent years. AI drug discovery remains in its early stages. Rather than betting on static valuations of individual pipelines, we back teams that do the right things throughout the process. We see that rare quality in Tushen Zhihe. Its founders combine AI and biotechnology backgrounds and have fundamentally rebuilt the loop of AI-driven design, experimental validation and data feedback. The Shanghai Antibody Superfactory co-built with industry partners demonstrates its full-stack capability in proprietary models, computational/wet-lab loops and scaled pipeline advancement, matching our strategy of original deep-tech innovation. We look forward to connecting capital and industrial resources to accelerate platform iteration and pipeline development, energizing Shanghai’s biopharmaceutical industry. We will continue supporting outstanding technology founders with long-term capital, helping Chinese original innovators grow from technology followers into global pharmaceutical leaders.”

Sino Biopharmaceutical said: “Our AI ecosystem strategy combines investment, internal R&D and collaboration, with AI now spanning research, production and commercialization. Tushen Zhihe’s technical depth and commercialization efficiency in protein design are impressive. ToursynClaw’s progress on difficult-to-drug targets aligns closely with our strategy. Through industrial collaboration, we hope to integrate its AI-design capabilities with our innovative-drug development system and bring more medicines from algorithms toward the clinic.”

Jinding Capital said: “Jinding Capital has long been deeply involved in industrial investment. We continue to focus on teams that genuinely possess underlying technological barriers to entry and the ability to turn their work into industrial applications. The engineering mindset and computational/wet-lab closed-loop capabilities that Tushen Zhihe has demonstrated in AI protein design are notably rare among comparable companies. We look forward to bringing the perspective and resources of industrial investment to accompany Tushen Zhihe through the critical stage from technology to products, and to help the company achieve broader industrial deployment in biomanufacturing and biopharmaceuticals.”

MegaRobo said: “AI’s ability to propose scientific hypotheses is advancing rapidly, but real-world validation has not kept pace. The key AI-for-Science bottleneck is shifting from model capability to real-world feedback. Closing that gap requires a continuously operating, continuously learning scientific-discovery system.” Tushen Zhihe allows protein designs to be tested and iterated in real experiments, complementing MegaRobo’s real-world intelligence infrastructure. Hypothesis generation, experimental execution, observation and accumulated learning operate within one loop, making every experiment part of scientific data. The strategic investment will deepen that collaboration. “We look forward to efficiently connecting AI design with real experiments, making each experiment part of scientific discovery’s continuing accumulation and evolution.”

Zero2IPO Holdings said: “We focus on early- and mid-stage investment and have followed national policy directions closely, particularly new technologies and business models. Tushen Zhihe’s early positioning and execution in the intersection of AI and protein design show the potential for AI plus life sciences to move from concepts into products. Its approach combines domestic chips with computational/wet-lab engineering, offering both technological independence and industrial practicality. With early-investor patience and resources, we will support its sustained work in AI drug discovery and growth into a globally competitive AI protein-design company.”

Shanghai State-owned Capital Investment Empowerment Company said: “Together with Shanghai Science and Technology Innovation Group, we provide comprehensive support across technology companies’ development lifecycle. This has produced concrete results for Tushen Zhihe. In foundational support, we jointly invited it to the first AI-for-Science ‘Hundred Teams, Hundred Projects’ innovation camp; recommended it for the municipal economy and informatization commission’s AI4S program, the Shenzhi Cup and the Haiju Talent competition’s AI4S track; brought it to Shanghai State-owned Capital Investment’s exhibition area at WAIC 2026; and arranged mainstream-media interviews and PowerVoice coverage. In strategic support, we connected it with affiliated funds and facilitated strategic cooperation frameworks with ecosystem companies, preparing capital and industrial resources for subsequent R&D and pipeline development. Through broadly accessible foundational services, specialized core services and comprehensive strategic services, we hope to continue supporting its platform and pipelines and energizing Shanghai AI4S.”

Kaicheng Capital said: “Thank you to the team for trusting us; we are honored to serve as exclusive financial adviser. AI for Science is moving from proof of concept to commercialization, and AI protein design offers particularly strong industrialization prospects and substantial potential. The company has made protein design a verifiable, iterable, scalable engineering system, combining top algorithms, closed-loop laboratory engineering and a clear commercialization path—an unusual combination in this field. Upholding long-term partnership, working together and shared success, we will continue contributing our expertise and industrial resources at the intersection of healthcare and AI, helping it become a global leader in AI protein design.”

This article was originally published by Synced. Author: Synced.

Related topics

After reading

Join the AINRK community

Read how to join the community and connect with people working in AI.

Community information (opens in a new tab)